Adjuvante und neoadjuvante Therapie des Melanoms

Dirk Debus; Axel Hauschild; Erwin S. Schultz

doi:10.1055/a-2453-8887

Adjuvante und neoadjuvante Therapie des Melanoms

Translated title of the contribution: Adjuvant and neoadjuvant therapy of melanoma

Dirk Debus (First author), Axel Hauschild, Erwin S. Schultz^* (Last author)

^*Corresponding author for this work

Department of Dermatology

FH Kiel University of Applied Sciences

Research output: Contribution to journal › Original Article › peer-review

Abstract

The treatment of malignant melanoma with (neo-)adjuvant therapy represents a promising approach to reducing recurrence and metastasis. At the same time, due to the risk of potential side effects, a risk-benefit assessment is required in advance, taking into account the stage-dependent risk of recurrence. The article presents the current study situation on adjuvant and neoadjuvant therapy.

Translated title of the contribution	Adjuvant and neoadjuvant therapy of melanoma
Original language	German
Pages (from-to)	555-561
Number of pages	7
Journal	DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
Volume	150
Issue number	10
DOIs	https://doi.org/10.1055/a-2453-8887
Publication status	Published - May 2025

Access to Document

10.1055/a-2453-8887

Cite this

@article{00a26a6010304ca2a68f9e6e9773640d,

title = "Adjuvante und neoadjuvante Therapie des Melanoms",

abstract = "The treatment of malignant melanoma with (neo-)adjuvant therapy represents a promising approach to reducing recurrence and metastasis. At the same time, due to the risk of potential side effects, a risk-benefit assessment is required in advance, taking into account the stage-dependent risk of recurrence. The article presents the current study situation on adjuvant and neoadjuvant therapy.",

keywords = "Adjuvant, Melanoma, Neoadjuvant, Pathological remission, Risk-benefit assessment",

author = "Dirk Debus and Axel Hauschild and Schultz, {Erwin S.}",

note = "Debus, Schultz: Derma- tologie der Paracelsus Medizinischen Privatuni- versit{\"a}t, Klinikum N{\"u}rnberg",

year = "2025",

month = may,

doi = "10.1055/a-2453-8887",

language = "Deutsch",

volume = "150",

pages = "555--561",

journal = "DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT",

issn = "0012-0472",

publisher = "Thieme Medical Publishers, US ",

number = "10",

}

TY - JOUR

T1 - Adjuvante und neoadjuvante Therapie des Melanoms

AU - Debus, Dirk

AU - Hauschild, Axel

AU - Schultz, Erwin S.

N1 - Debus, Schultz: Derma- tologie der Paracelsus Medizinischen Privatuni- versität, Klinikum Nürnberg

PY - 2025/5

Y1 - 2025/5

N2 - The treatment of malignant melanoma with (neo-)adjuvant therapy represents a promising approach to reducing recurrence and metastasis. At the same time, due to the risk of potential side effects, a risk-benefit assessment is required in advance, taking into account the stage-dependent risk of recurrence. The article presents the current study situation on adjuvant and neoadjuvant therapy.

AB - The treatment of malignant melanoma with (neo-)adjuvant therapy represents a promising approach to reducing recurrence and metastasis. At the same time, due to the risk of potential side effects, a risk-benefit assessment is required in advance, taking into account the stage-dependent risk of recurrence. The article presents the current study situation on adjuvant and neoadjuvant therapy.

KW - Adjuvant

KW - Melanoma

KW - Neoadjuvant

KW - Pathological remission

KW - Risk-benefit assessment

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001472748200011&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1055/a-2453-8887

DO - 10.1055/a-2453-8887

M3 - Originalarbeit

C2 - 40262754

SN - 0012-0472

VL - 150

SP - 555

EP - 561

JO - DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

JF - DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

IS - 10

ER -

Adjuvante und neoadjuvante Therapie des Melanoms

Abstract

Access to Document

Other files and links

Fingerprint

Cite this